

Remarks

Currently Claims 1-14, 16-17 and 20-22 are pending. Claims 15 and 18-19 are cancelled.

The specification has been amended to recite the claim of priority and to include an abstract on a separate page.

Claims 2-14 and 16-17 are amended herein. Claim 2 is amended to change plural to singular for the purpose of correcting grammar. Claims 3-10, 12-14 and 16-17 are amended to remove multiple dependencies for the purpose of reducing claim fees. Claim 11 is amended to insert "and" prior to the last compound name for the purpose of correcting grammar. Claims 14 and 16-17 have been further amended to remove a redundant expression. The foregoing amendments do not narrow the scope of the claims and are not made for purposes of patentability. No new matter is added.

New claims 20-22 are added, support for which can be found throughout Applicant's original specification, including at original claims 14, 16 and 17. No new matter is added.

Applicant respectfully submits that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at 919 483-8222, to discuss this case further if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 14 January, 2005
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988